Drug Type Small molecule drug |
Synonyms MAPKAP-K2 inhibiting carboline/ pyrazinoindolone analogs(Boehringer Ingelheim), MK-2 inhibiting carboline/ pyrazinoindolone analogs(Boehringer Ingelheim), p38 MAPK and MAPKAP-K2 inhibitors (inflammatory dise) |
Target |
Action inhibitors |
Mechanism MAPKAPK2 inhibitors(MAP kinase-activated protein kinase 2 inhibitors), p38α inhibitors(P38 α mitogen-activated protein kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Inflammation | Discovery | United States | - |





